Clinical Trials Browser

Phase 1 × Esophageal Neoplasms × Oxaliplatin × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05891171 2026-02-27

ARC-25

Phase 1 Active not recruiting

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03153280 2025-07-08

Lithium

Phase 1 Terminated

2 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Phase 1 Completed

9 enrolled

Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02347904 2019-11-18

SOX

Phase 1 Completed

40 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Phase 1 Completed

66 enrolled

GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT01386346 2018-12-12

VEOX

Phase 1 Completed

12 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT01561014 2018-07-02

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 1 Completed

9 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00003427 2013-06-26

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

Phase 1 Completed

36 enrolled

Gastrointestinal

Anus Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00732745 2011-08-22

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 1 Terminated

9 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

ARC-25

Lithium

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

SOX

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

VEOX

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction